RA Capital Healthcare Fund, L.P. v. ChemoCentryx, Inc.

I. BACKGROUND

18 Plaintiff alleges that it suffered tens of millions of dollars in investment losses as a result of 19 false and misleading statements and omissions made by Defendants regarding ChemoCentryx’s 20 major new drug avacopan. See ECF No. 1 ¶ 1. It asserts claims for violation of Section 10(b) of 21 the Exchange Act and Rule 10b-5(b); violation of Section 10(b) of the Exchange Act and 22 Rule 10b-5(a) and (c); violation of Section 20(a) of the Exchange Act; violation of Section 20A of 23 the Exchange Act; violation of Section 18 of the Exchange Act; fraud; negligent 24 misrepresentation; and violation of California Civil Code § 1709. Id. ¶¶ 385-465. 25 Three years before Plaintiff filed this lawsuit, Lead Plaintiff Indiana Public Retirement 26 System (“IPRS”) filed in this Court Homyk v. ChemoCentryx, Inc., Case No. 21-cv-03343 (the 27 “Class Action”), an action individually and on behalf of all persons who purchased or otherwise acquired ChemoCentryx common stock between November 26, 2019, and May 6, 2021. In that action, IPRS raises essentially identical allegations as those asserted by Plaintiff here—that Defendants violated Sections 10(b) and 20(a)…